Compare TAYD & IMUX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TAYD | IMUX |
|---|---|---|
| Founded | 1955 | 2016 |
| Country | United States | United States |
| Employees | 135 | 66 |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 193.6M | 155.8M |
| IPO Year | 1995 | 2013 |
| Metric | TAYD | IMUX |
|---|---|---|
| Price | $56.80 | $6.88 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 12 |
| Target Price | N/A | ★ $43.09 |
| AVG Volume (30 Days) | 36.6K | ★ 392.9K |
| Earning Date | 10-02-2026 | 11-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 38.00 |
| EPS | ★ 0.14 | N/A |
| Revenue | ★ $41,649,673.00 | N/A |
| Revenue This Year | $40.70 | N/A |
| Revenue Next Year | $13.65 | N/A |
| P/E Ratio | $428.07 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $40.50 | $0.51 |
| 52 Week High | $90.37 | $17.43 |
| Indicator | TAYD | IMUX |
|---|---|---|
| Relative Strength Index (RSI) | 42.77 | 24.48 |
| Support Level | $50.17 | $0.83 |
| Resistance Level | $60.72 | $15.82 |
| Average True Range (ATR) | 2.89 | 0.63 |
| MACD | -0.50 | 0.02 |
| Stochastic Oscillator | 48.04 | 0.17 |
Taylor Devices Inc is engaged in the design, development, manufacture and marketing of shock absorption, rate control, and energy storage devices for use in various types of machinery, equipment and structures. The company continues to develop new and technology products. The company manufactures and sells a group of very similar products that have many different applications for customers. These similar products are included in one of nine categories, namely, Seismic Dampers, Fluidicshoks, Crane and Industrial Buffers, Self-Adjusting Shock Absorbers, Liquid Die Springs, Vibration Dampers, Machined Springs, Custom Shock and Vibration Isolators, and Custom Actuators. It has presence in USA, Asia, and Others. Majority of revenue comes from USA.
Immunic Inc is a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases, including ulcerative colitis, Crohn's disease, relapsing-remitting multiple sclerosis, and psoriasis. The company is developing small molecule products, which include IMU-838, which is a selective immune modulator that inhibits the intracellular metabolism of activated immune cells by blocking the enzyme DHODH; IMU-935 is an inverse agonist of RORyt, and IMU-856 targets the restoration of the intestinal barrier function. It operates in one segment which is Life science segment.